QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.020990v1 69/5/1709    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kamiya, K. Articles by Sanguinetti, M. C. Search for Related Content PubMed PubMed Citation Articles by Kamiya, K. Articles by Sanguinetti, M. C.

Molecular Determinants of hERG Channel Block

Department of Humeral Regulation, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan (K.K., R.N.); Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, United Kingdom (J.S.M.); and Department of Physiology and Nora Eccles Harrison Cardiovascular Research & Training Institute, University of Utah, Salt Lake City, Utah (M.C.S.)

Drug-induced block of cardiac hERG K⁺ channels causes acquired long QT syndrome. Here, we characterized the molecular mechanism of hERG block by two low-potency drugs (Nifekalant and bepridil) and two high-potency drugs 1-[2-(6-methyl-2pyridyl)ethyl]-4-(4-methylsulfonyl aminobenzoyl)piperidine (E-4031) and dofetilide). Channels were expressed in Xenopus laevis oocytes, and currents were measured using the two-microelectrode voltage-clamp technique. All four drugs progressively reduced hERG current during a 20-s depolarization to 0 mV after a 10-min pulse-free period, consistent with the preferential block of open channels. Recovery from block in response to pulses to -160 mV was observed for D540K hERG channels but not for wild-type hERG channels, suggesting that all four drugs are trapped in the central cavity by closure of the activation gate. The molecular determinants of hERG channel block were defined by using a site-directed mutagenesis approach. Mutation to alanine of three residues near the pore helix (Thr623, Ser624, and Val625) and four residues in Ser6 (Gly648, Tyr652, Phe656, and Val659) reduced channel sensitivity to block by dofetilide and E-4031, effects identical with those reported previously for two other methanesulfonanilides, (+)- N -[1' -(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydroxyspiro(2H -1-benzopyran-2,4' -piperidin)-6-yl]-methanesulfonamide] monohydrochloride (MK-499) and ibutilide. The effect of nifekalant on mutant channels was similar, except that V659A retained normal sensitivity and I655A channels were less sensitive. Finally, mutation of the three residues near the pore helix and Phe656 in the Ser6 domain reduced channel block by bepridil. We conclude that the binding site is not identical for all drugs that preferentially block hERG in the open state.

Address correspondence to: Dr. Kaichiro Kamiya, Department of Humoral Regulation, Research Institute of Environmental Medicine, Nagoya University. E-mail: kamiya{at}riem.nagoya-u.ac.jp

This article has been cited by other articles:

				H. Sale, J. Wang, T. J. O'Hara, D. J. Tester, P. Phartiyal, J.-Q. He, Y. Rudy, M. J. Ackerman, and G. A. Robertson Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome Circ. Res., September 26, 2008; 103(7): e81 - e95. [Abstract] [Full Text] [PDF]

				J. Kurokawa, M. Tamagawa, N. Harada, S.-i. Honda, C.-X. Bai, H. Nakaya, and T. Furukawa Acute effects of oestrogen on the guinea pig and human IKr channels and drug-induced prolongation of cardiac repolarization J. Physiol., June 15, 2008; 586(12): 2961 - 2973. [Abstract] [Full Text] [PDF]

				X. Xu, M. Recanatini, M. Roberti, and G.-N. Tseng Probing the Binding Sites and Mechanisms of Action of Two Human Ether-a-go-go-Related Gene Channel Activators, 1,3-bis-(2-Hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243) Mol. Pharmacol., June 1, 2008; 73(6): 1709 - 1721. [Abstract] [Full Text] [PDF]

				E. L. Strevel, D. J. Ing, and L. L. Siu Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371. [Abstract] [Full Text] [PDF]

				R. S. Hansen, S.-P. Olesen, and M. Grunnet Pharmacological Activation of Rapid Delayed Rectifier Potassium Current Suppresses Bradycardia-Induced Triggered Activity in the Isolated Guinea Pig Heart J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 996 - 1002. [Abstract] [Full Text] [PDF]